Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation.
Vandecasteele K, De Neve W, De Gersem W, Delrue L, Paelinck L, Makar A, Fonteyne V, De Wagter C, Villeirs G, De Meerleer G. Vandecasteele K, et al. Among authors: de gersem w, de meerleer g, de neve w, de wagter c. Strahlenther Onkol. 2009 Dec;185(12):799-807. doi: 10.1007/s00066-009-1986-8. Strahlenther Onkol. 2009. PMID: 20013089
Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experience.
De Meerleer G, Vandecasteele K, Ost P, Delrue L, Denys H, Makar A, Speleers B, Van Belle S, Van den Broecke R, Fonteyne V, De Neve W. De Meerleer G, et al. Among authors: de neve w. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):775-81. doi: 10.1016/j.ijrobp.2009.11.039. Epub 2010 Apr 24. Int J Radiat Oncol Biol Phys. 2011. PMID: 20421155
Value of magnetic resonance and ¹⁸FDG PET-CT in predicting tumor response and resectability of primary locally advanced cervical cancer after treatment with intensity-modulated arc therapy: a prospective pathology-matched study.
Vandecasteele K, Delrue L, Lambert B, Makar A, Lambein K, Denys H, Tummers P, Van den Broecke R, Villeirs G, De Meerleer G. Vandecasteele K, et al. Among authors: de meerleer g. Int J Gynecol Cancer. 2012 May;22(4):630-7. doi: 10.1097/IGC.0b013e3182428925. Int J Gynecol Cancer. 2012. PMID: 22237382
Postoperative intensity-modulated arc therapy for cervical and endometrial cancer: a prospective report on toxicity.
Vandecasteele K, Tummers P, Makar A, van Eijkeren M, Delrue L, Denys H, Lambert B, Beerens AS, Van den Broecke R, Lambein K, Fonteyne V, De Meerleer G. Vandecasteele K, et al. Among authors: de meerleer g. Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):408-14. doi: 10.1016/j.ijrobp.2011.12.020. Epub 2012 Feb 28. Int J Radiat Oncol Biol Phys. 2012. PMID: 22377596
Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer. Toxicity, tumour response and outcome.
Vandecasteele K, Makar A, Van den Broecke R, Delrue L, Denys H, Lambein K, Lambert B, van Eijkeren M, Tummers P, De Meerleer G. Vandecasteele K, et al. Among authors: de meerleer g. Strahlenther Onkol. 2012 Jul;188(7):576-81. doi: 10.1007/s00066-012-0097-0. Epub 2012 Apr 19. Strahlenther Onkol. 2012. PMID: 22526231 Clinical Trial.
198 results